
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6492183/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Serious Puzzle Game to Enhance Adherence to Antirheumatic Drugs in Patients With Rheumatoid Arthritis: Systematic Development Using Intervention Mapping. JMIR Serious Games, 2022, 10, e31570.	1.7	2
2	Drug levels, anti-drug antibodies and B-cell counts were not predictive of response in rheumatoid arthritis patients on (ultra-)low-doseâ€,rituximab. Rheumatology, 2022, 61, 3974-3980.	0.9	7
3	Effectiveness of electronic drug monitoring feedback to increase adherence in patients with RA initiating a biological DMARD: a randomised clinical trial. RMD Open, 2022, 8, e001712.	1.8	3
4	Commentary on the EMA reflection paper on the pharmaceutical development of medicines for use in the older population. British Journal of Clinical Pharmacology, 2022, , .	1.1	4
5	Implementation of a pharmacistâ€led transitional pharmaceutical care programme: Process evaluation of Medication Actions to Reduce hospital admissions through a collaboration between Community and Hospital pharmacists (MARCH). Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 1049-1069.	0.7	2
6	The effect of Patient's Own Medication use on patient's self-reported medication knowledge during hospitalisation: a pre-post intervention study. BMC Health Services Research, 2022, 22, 423.	0.9	2
7	Barriers and facilitators for the usage of a personal health record for medication reconciliation: a qualitative study among patients. British Journal of Clinical Pharmacology, 2022, , .	1.1	2
8	Are Health Care Professionals' Implicit and Explicit Attitudes Toward Conventional Diseaseâ€Modifying Antirheumatic Drugs Associated With Those of Their Patients?. Arthritis Care and Research, 2021, 73, 364-373.	1.5	3
9	Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: A cross-sectional study in patients with atrial fibrillation. Patient Education and Counseling, 2021, 104, 155-162.	1.0	19
10	Association between healthcare practitioners' beliefs about statins and patients' beliefs and adherence. British Journal of Clinical Pharmacology, 2021, 87, 1082-1088.	1.1	5
11	Effect of Interactive eHealth Interventions on Improving Medication Adherence in Adults With Long-Term Medication: Systematic Review. Journal of Medical Internet Research, 2021, 23, e18901.	2.1	50
12	A comparison between medication reconciliation by a pharmacy technician and the use of an online personal health record by patients for identifying medication discrepancies in patients' drug lists prior to elective admissions. International Journal of Medical Informatics, 2021, 147, 104370.	1.6	12
13	Impact of Ramadan Intermittent Fasting on the Heart Rate Variability and Cardiovascular Parameters of Patients with Controlled Hypertension. Journal of Nutrition and Metabolism, 2021, 2021, 1-10.	0.7	11
14	Medication-Related Hospital Readmissions Within 30â€,Days of Discharge: Prevalence, Preventability, Type of Medication Errors and Risk Factors. Frontiers in Pharmacology, 2021, 12, 567424.	1.6	26
15	Electronic Monitoring Feedback for Improving Medication Adherence and Clinical Outcomes in Early Rheumatoid Arthritis: A Randomized Clinical Trial. Patient Preference and Adherence, 2021, Volume 15, 1107-1119.	0.8	4
16	Angiotensin-Inhibiting Drugs Do Not Impact Disease Activity in Patients with Rheumatoid Arthritis: A Retrospective Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 1985.	1.0	4
17	The effect of a transitional pharmaceutical care program on the occurrence of ADEs after discharge from hospital in patients with polypharmacy. Research in Social and Administrative Pharmacy, 2021, 18, 2651-2651.	1.5	3
18	Gastrointestinal Adverse Drug Reaction Profile of Etanercept: Real-world Data From Patients and Healthcare Professionals. Journal of Rheumatology, 2021, 48, 1388-1394.	1.0	2

#	Article	IF	CITATIONS
19	Patient Perspectives on Outcome Domains of Medication Adherence Trials in Inflammatory Arthritis: An International OMERACT Focus Group Study. Journal of Rheumatology, 2021, 48, 1480-1487.	1.0	0
20	Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial. Trials, 2021, 22, 406.	0.7	1
21	Impact of Fasting on Cardiovascular Outcomes in Patients With Hypertension. Journal of Cardiovascular Pharmacology, 2021, 78, 481-495.	0.8	6
22	Infliximab use in the Netherlands: Uptake and characteristics of originator and biosimilars over time. British Journal of Clinical Pharmacology, 2021, , .	1.1	1
23	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. Annals of the Rheumatic Diseases, 2021, 80, 707-713.	0.5	30
24	Application of intervention mapping to develop and evaluate a pharmaceutical discharge letter to improve information transfer between hospital and community pharmacists. Research in Social and Administrative Pharmacy, 2021, , .	1.5	1
25	Interventions to support shared decision making for medication therapy in long term conditions: A systematic review. Patient Education and Counseling, 2020, 103, 254-265.	1.0	21
26	Patient and Caregiver Priorities for Medication Adherence in Gout, Osteoporosis, and Rheumatoid Arthritis: Nominal Group Technique. Arthritis Care and Research, 2020, 72, 1410-1419.	1.5	19
27	Diagnostic accuracy of a singleâ€lead portable ECG device for measuring QTc prolongation. Annals of Noninvasive Electrocardiology, 2020, 25, e12683.	0.5	15
28	Patients' and providers' perspectives on medication relatedness and potential preventability of hospital readmissions within 30 days of discharge. Health Expectations, 2020, 23, 212-219.	1.1	4
29	The development of a test battery to assess the hand–eye functions relevant in predicting easy and accurate tablet subdivision in older people: A pilot study. British Journal of Clinical Pharmacology, 2020, 86, 1969-1981.	1.1	9
30	Scope of Outcomes in Trials and Observational Studies of Interventions Targeting Medication Adherence in Rheumatic Conditions: A Systematic Review. Journal of Rheumatology, 2020, 47, 1565-1574.	1.0	15
31	Stakeholders' perspectives on a patient-reported outcome measure-based drug safety monitoring system for immune-mediated inflammatory diseases. Expert Opinion on Drug Safety, 2020, 19, 1521-1528.	1.0	2
32	Information needs and patient perceptions of the quality of medication information available in hospitals: a mixed method study. International Journal of Clinical Pharmacy, 2020, 42, 1396-1404.	1.0	11
33	Patients with inflammatory rheumatic diseases: quality of self-reported medical information in a prospective cohort event monitoring system. Rheumatology, 2020, 59, 1253-1261.	0.9	15
34	Patient-Reported Burden of Adverse Drug Reactions Attributed to Biologics Used for Immune-Mediated Inflammatory Diseases. Drug Safety, 2020, 43, 917-925.	1.4	20
35	Drug utilization in the Maastricht Study. Medicine (United States), 2020, 99, e18524.	0.4	1
36	Shared decision making in routine clinical care of patients with rheumatoid arthritis: an assessment of audio-recorded consultations. Annals of the Rheumatic Diseases, 2020, 79, 170-175.	0.5	29

#	Article	IF	CITATIONS
37	Effect of Ramadan fasting on heart rate variability as a measure of cardiac stress in a Lebanese cohort. European Journal of Clinical Nutrition, 2020, 74, 1237-1239.	1.3	6
38	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. RMD Open, 2020, 6, e001432.	1.8	23
39	The Association Between Î ² -Blocker Use and Cardiorespiratory Fitness: The Maastricht Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2019, 24, 37-45.	1.0	6
40	Medication management issues identified during home medication reviews for ambulatory community pharmacy patients. Canadian Pharmacists Journal, 2019, 152, 334-342.	0.4	9
41	<p>Preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: a discrete choice experiment</p> . Patient Preference and Adherence, 2019, Volume 13, 1199-1211.	0.8	16
42	Ultra-low doses of rituximab for continued treatment of rheumatoid arthritis (REDO study): a randomised controlled non-inferiority trial. Lancet Rheumatology, The, 2019, 1, e145-e153.	2.2	19
43	Economic impact of Patient's Own Medication use during hospitalisation: a multicentre pre-post implementation study. International Journal of Clinical Pharmacy, 2019, 41, 1658-1665.	1.0	12
44	Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. Diabetes Research and Clinical Practice, 2019, 148, 240-248.	1.1	2
45	Creating an Interprofessional guideline to support patients receiving oral anticoagulation therapy: a Delphi exercise. International Journal of Clinical Pharmacy, 2019, 41, 1012-1020.	1.0	7
46	What does it cost to redispense unused medications in the pharmacy? A micro-costing study. BMC Health Services Research, 2019, 19, 243.	0.9	17
47	Validity of a nationwide medication record system in the Netherlands. International Journal of Clinical Pharmacy, 2019, 41, 687-690.	1.0	17
48	Barriers and facilitators with medication use during the transition from hospital to home: a qualitative study among patients. BMC Health Services Research, 2019, 19, 204.	0.9	41
49	The effect of a pharmacy-led transitional care program on medication-related problems post-discharge: A before—After prospective study. PLoS ONE, 2019, 14, e0213593.	1.1	50
50	A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience. Drug Delivery, 2019, 26, 384-392.	2.5	60
51	Redispensing of unused HIV post-exposure prophylaxis for medical students. Travel Medicine and Infectious Disease, 2019, 29, 82-83.	1.5	4
52	FRI0097â€RA PATIENTS' PERSPECTIVES ON BIOLOGICAL DMARD-INDUCED ADVERSE DRUG REACTIONS AN THEIR BURDEN. , 2019, , .	۱D	0
53	LB0010â€ULTRA-LOW DOSES OF RITUXIMAB OR RETREATMENT OF RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL. , 2019, , .		0
54	SP0038â€FACTORS IMPORTANT FOR MEDICAL ADHERENCE. , 2019, , .		0

5

#	Article	IF	CITATIONS
55	Willingness of patients to use unused medication returned to the pharmacy by another patient: a cross-sectional survey. BMJ Open, 2019, 9, e024767.	0.8	22
56	Performance of idarucizumab as antidote of dabigatran in daily clinical practice. Europace, 2019, 21, 414-420.	0.7	31
57	Quantity and economic value of unused oral anti-cancer and biological disease-modifying anti-rheumatic drugs among outpatient pharmacy patients who discontinue therapy. Research in Social and Administrative Pharmacy, 2019, 15, 100-105.	1.5	22
58	Prevalence and Preventability of Drugâ€Related Hospital Readmissions: A Systematic Review. Journal of the American Geriatrics Society, 2018, 66, 602-608.	1.3	135
59	Open‣abel, Nonâ€Mandatory Transitioning From Originator Etanercept to Biosimilar <scp>SB</scp> 4. Arthritis and Rheumatology, 2018, 70, 1408-1418.	2.9	90
60	Older Patients' Compliance with Drug Storage Recommendations. Drugs and Aging, 2018, 35, 233-241.	1.3	16
61	Therapeutic drug monitoring of biologicals in rheumatoid arthritis: a disconnect between beliefs and facts. Current Opinion in Rheumatology, 2018, 30, 266-275.	2.0	18
62	Effect of Pharmacist-Led Interventions on (Non)Motor Symptoms, Medication-Related Problems, and Quality of Life in Parkinson Disease Patients: A Pilot Study. Clinical Neuropharmacology, 2018, 41, 14-19.	0.2	11
63	Outcome Measures in Rheumatology - Interventions for medication Adherence (OMERACT-Adherence) Core Domain Set for Trials of Interventions for Medication Adherence in Rheumatology: 5 Phase Study Protocol. Trials, 2018, 19, 204.	0.7	23
64	Use of parenteral glucocorticoids and the risk of new onset type 2 diabetes mellitus: A case-control study. Diabetes Research and Clinical Practice, 2018, 139, 100-106.	1.1	0
65	Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open‣abel Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis and Rheumatology, 2018, 70, 60-68.	2.9	142
66	Comment on l'Ami <i>et al</i> titled 'Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial'. Annals of the Rheumatic Diseases, 2018, 77, e67-e67.	0.5	1
67	A discrete choice experiment on preferences of patients with rheumatoid arthritis regarding disease-modifying antirheumatic drugs: the identification, refinement and selection of attributes and levels. Patient Preference and Adherence, 2018, Volume 12, 1537-1555.	0.8	11
68	Pharmacists' Activities to Reduce Medication Waste: An International Survey. Pharmacy (Basel,) Tj ETQqO O () rgBT /Ov	erlock 10 Tf S
69	Support needs for medication use and the suitability of eHealth technologies to address these needs: a focus group study of older patients with rheumatoid arthritis. Patient Preference and Adherence, 2018, Volume 12, 349-358.	0.8	19
70	Pharmacokinetics of 400 mg Locally Infiltrated Ropivacaine After Total Knee Arthroplasty Without Perioperative Tourniquet Use. Regional Anesthesia and Pain Medicine, 2018, 43, 1.	1.1	9
71	Redispensing of medicines unused by patients: a qualitative study among stakeholders. International Journal of Clinical Pharmacy, 2017, 39, 196-204.	1.0	27

Pharmacokinetics of 400 mg ropivacaine after periarticular local infiltration analgesia for total knee arthroplasty. Acta Anaesthesiologica Scandinavica, 2017, 61, 338-345. 72 0.7 27

#	Article	IF	CITATIONS
73	Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 843-857.	1.5	17
74	Supporting adherence to oral anticancer agents: clinical practice and clues to improve care provided by physicians, nurse practitioners, nurses and pharmacists. BMC Cancer, 2017, 17, 122.	1.1	30
75	The effect of electronic monitoring feedback on medication adherence and clinical outcomes: A systematic review. PLoS ONE, 2017, 12, e0185453.	1.1	55
76	Ultra-low dose of rituximab in rheumatoid arthritis: study protocol for a randomised controlled trial. Trials, 2017, 18, 403.	0.7	18
77	Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?. PLoS ONE, 2017, 12, e0171070.	1.1	30
78	Rheumatologists' beliefs about medication barely differ from patients' medication beliefs. European Journal for Person Centered Healthcare, 2017, 5, 308.	0.3	3
79	Disentangling Rheumatoid Arthritis Patients' Implicit and Explicit Attitudes toward Methotrexate. Frontiers in Pharmacology, 2016, 7, 233.	1.6	16
80	Matching Adherence Interventions to Patient Determinants Using the Theoretical Domains Framework. Frontiers in Pharmacology, 2016, 7, 429.	1.6	47
81	Nonadherence to disease modifying antirheumatic drugs in the first year after diagnosis: comparing three adherence measures in early arthritis patients. Rheumatology, 2016, 55, 1812-1819.	0.9	27
82	Severity of Diabetes Mellitus and Total Hip or Knee Replacement. Medicine (United States), 2016, 95, e3739.	0.4	24
83	Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case–control study. British Journal of Clinical Pharmacology, 2016, 81, 370-378.	1.1	18
84	The majority of patients do not store their biologic disease-modifying antirheumatic drugs within the recommended temperature range. Rheumatology, 2016, 55, 704-709.	0.9	45
85	Safety and efficacy of new oral anticoagulants and lowâ€molecularâ€weight heparins compared with aspirin in patients undergoing total knee and hip replacements. Pharmacoepidemiology and Drug Safety, 2016, 25, 1245-1252.	0.9	22
86	Barriers and facilitators to disease-modifying antirheumatic drug use in patients with inflammatory rheumatic diseases: a qualitative theory-based study. BMC Musculoskeletal Disorders, 2016, 17, 442.	0.8	28
87	Beliefs about inhaled corticosteroids: Comparison of community pharmacists, pharmacy technicians and patients with asthma. Journal of Asthma, 2016, 53, 1051-1058.	0.9	9
88	Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study. Annals of the Rheumatic Diseases, 2016, 75, 1939-1944.	0.5	46
89	Adherence to oral anticancer agents: Healthcare providers' perceptions, beliefs and shared decision making in Belgium and the Netherlands. Acta Oncológica, 2016, 55, 437-443.	0.8	8
90	Identification of antithrombotic drugs related to total joint replacement using anonymised free-text notes: a search strategy in the Clinical Practice Research Datalink. BMJ Open, 2015, 5, e009017.	0.8	2

#	Article	IF	CITATIONS
91	Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease. Arthritis Research and Therapy, 2015, 17, 281.	1.6	58
92	Identifying the Optimal Role for Pharmacists in Care Transitions: A Systematic Review. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 614-638.	0.5	84
93	Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2015, 74, 2260-2261.	0.5	15
94	Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ, The, 2015, 350, h1389-h1389.	3.0	135
95	Patient-centred care in established rheumatoid arthritis. Best Practice and Research in Clinical Rheumatology, 2015, 29, 643-663.	1.4	99
96	Authors' response to the letter from Kalleian Eserian et al. International Journal of Pharmaceutics, 2015, 478, 682-683.	2.6	0
97	Perceived need to take medication is associated with medication non-adherence in patients with rheumatoid arthritis. Patient Preference and Adherence, 2014, 8, 1635.	0.8	46
98	Psychosocial predictors of non-adherence to chronic medication: systematic review of longitudinal studies. Patient Preference and Adherence, 2014, 8, 519.	0.8	24
99	The accuracy, precision and sustainability of different techniques for tablet subdivision: Breaking by hand and the use of tablet splitters or a kitchen knife. International Journal of Pharmaceutics, 2014, 466, 44-51.	2.6	73
100	Effectiveness of a group-based intervention to change medication beliefs and improve medication adherence in patients with rheumatoid arthritis: A randomized controlled trial. Patient Education and Counseling, 2014, 94, 356-361.	1.0	55
101	Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. The Cochrane Library, 2014, , CD010455.	1.5	61
102	Antidrug antibodies to tumour necrosis factor specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective; comment on the article by Vincent <i>et al</i> . Annals of the Rheumatic Diseases, 2013, 72, e14-e14.	0.5	4
103	The combined use of disease activity and infliximab serum trough concentrations for early prediction of (nonâ€)response to infliximab in rheumatoid arthritis. British Journal of Clinical Pharmacology, 2013, 76, 939-945.	1.1	32
104	<scp>CNS</scp> effects of indomethacin: should patients be cautioned about decreased mental alertness and motor coordination?. British Journal of Clinical Pharmacology, 2013, 75, 814-821.	1.1	5
105	Pharmacokinetics of 450 mg ropivacaine with and without epinephrine for combined femoral and sciatic nerve block in lower extremity surgery. A pilot study. British Journal of Clinical Pharmacology, 2013, 75, 1321-1327.	1.1	21
106	Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study. BMC Musculoskeletal Disorders, 2013, 14, 299.	0.8	39
107	Down-titration and discontinuation of infliximab in rheumatoid arthritis patients with stable low disease activity and stable treatment: an observational cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1849-1854.	0.5	88
108	Medication adherence in patients with rheumatoid arthritis: a critical appraisal of the existing literature. Expert Review of Clinical Immunology, 2012, 8, 337-351.	1.3	240

#	Article	IF	CITATIONS
109	Dual-tasking interferes with obstacle avoidance reactions in healthy seniors. Gait and Posture, 2012, 36, 236-240.	0.6	39
110	Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study. BMC Musculoskeletal Disorders, 2012, 13, 184.	0.8	25
111	Development and content of a group-based intervention to improve medication adherence in non-adherent patients with rheumatoid arthritis. Patient Education and Counseling, 2012, 89, 143-151.	1.0	17
112	Making the rheumatologist aware of patients' non-adherence does not improve medication adherence in patients with rheumatoid arthritis. Scandinavian Journal of Rheumatology, 2011, 40, 192-196.	0.6	29
113	The effect of a non-steroidal anti-inflammatory drug on two important predictors for accidental falls: Postural balance and manual reaction time. A randomized, controlled pilot study. Human Movement Science, 2011, 30, 384-395.	0.6	10
114	Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study. BMC Musculoskeletal Disorders, 2011, 12, 12.	0.8	35
115	Unraveling the Association Between SSRI Use and Falls. Clinical Neuropharmacology, 2011, 34, 210-215.	0.2	17
116	Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology, 2010, 49, 1801-1803.	0.9	44
117	Gastroprotection among new chronic users of non-steroidal anti-inflammatory drugs: a study of utilization and adherence in the Netherlands. Current Medical Research and Opinion, 2009, 25, 195-204.	0.9	18
118	COXâ€2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors. Pharmacoepidemiology and Drug Safety, 2009, 18, 880-890.	0.9	11
119	Adherence Rates and Associations with Nonadherence in Patients with Rheumatoid Arthritis Using Disease Modifying Antirheumatic Drugs. Journal of Rheumatology, 2009, 36, 2164-2170.	1.0	120
120	NSAIDs and the Risk of Accidental Falls in the Elderly. Drug Safety, 2009, 32, 489-498.	1.4	37
121	Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. Annals of the Rheumatic Diseases, 2008, 67, 1697-1701.	0.5	46
122	How can we improve adherence to therapy by patients with rheumatoid arthritis?. Nature Clinical Practice Rheumatology, 2007, 3, 681-681.	3.2	37
123	InforMatrix®: treatment of rheumatoid arthritis using biologicals. Expert Opinion on Pharmacotherapy, 2006, 7, 1769-1789.	0.9	3